Biotech Values

[BTH]

Rindopepimut is simply a 13 amino acid peptide attached to a carrier protein (KLH in this case). So the body has to ramp up an immune response against this peptide. This has historically been a relatively failing proposition in producing an adaptive immune response: you get low titre B-cell derived antigen specific antibodies and a weak T cell response. This is very similar to BLP25.

Is there any way these two drugs you mention are doing something to the tumor, despite not ramping a very strong T cell response?